

## DAFTAR PUSTAKA

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin M, Piñeros M, *et al.* Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Vol. 144, International Journal of Cancer. Wiley-Liss Inc.; 2019. p. 1941–53.
2. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, *et al.* Global Cancer Observatory: Cancer Today [Internet]. International Agency for Research on Cancer. 2022 [cited 2024 Feb 3]. Available from: <https://gco.iarc.who.int/today>
3. Trinidad C V., Tetlow AL, Bantis LE, Godwin AK. Reducing ovarian cancer mortality through early detection: Approaches using circulating biomarkers. Vol. 13, Cancer Prevention Research, American Association for Cancer Research Inc.; 2020. p. 241–52.
4. Matsuo K, Matsuzaki S, Maeda M, Rau AR, Yoshihara K, Tamura R, *et al.* Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas. JAMA Netw Open [Internet]. 2023 Jun 16;6(6):e2318602–e2318602. Available from: <https://doi.org/10.1001/jamanetworkopen.2023.18602>
5. Sabelli C. Pap tests could be used to detect early ovarian cancer at the outset. Nature Italy. 2023 Dec 14;
6. Mahyenda N, Muhammad S, Asri A. Hubungan Skor RMI Dengan Stadium Kanker Ovarium Tipe Epitel Di RSUP Dr. M. Djamil Padang. Jurnal Ilmu Kesehatan Indonesia. 2023 Jan 19;3(3):210–6.
7. Wang Q, Feng X, Liu X, Zhu S. Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis. Front Oncol [Internet]. 2022;12. Available from: <https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.868061>
8. Markman M. The Role of CA-125 in the Management of Ovarian Cancer. Oncologist [Internet]. 1997 Feb 1;2(1):6–9. Available from: <https://doi.org/10.1634/theoncologist.2-1-6>
9. Fritsche HA, Bast RC. CA 125 in Ovarian Cancer: Advances and Controversy. Clin Chem [Internet]. 1998 Jul 1;44(7):1379–80. Available from: <https://doi.org/10.1093/clinchem/44.7.1379>
10. Tetkova A, Susor A, Kubelka M, Nemcova L, Jansova D, Dvoran M, *et al.* Follicle-stimulating hormone administration affects amino acid metabolism in mammalian oocytes. Biol Reprod. 2019 Oct 25;101(4):719–32.

11. Society for Endocrinology. Ovaries. <https://www.yourhormones.info/glands/ovaries/>. 2024.
12. Tavares V, Marques IS, Melo IG de, Assis J, Pereira D, Medeiros R. Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements. *Int J Mol Sci*. 2024 Feb 3;25(3):1845.
13. Romero I, Leskelä S, Mies BP, Velasco AP, Palacios J. Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications. *European Journal of Cancer Supplements* [Internet]. 2020;15:1–15. Available from: <https://www.sciencedirect.com/science/article/pii/S1359634920300021>
14. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. *Nat Rev Cancer* [Internet]. 2009;9(6):415–28. Available from: <https://doi.org/10.1038/nrc2644>
15. Ravindran F, Choudhary B. Ovarian Cancer: Molecular Classification and Targeted Therapy. In: Ho GY, Webber K, editors. *Ovarian Cancer* [Internet]. Rijeka: IntechOpen; 2021. p. Ch. 1. Available from: <https://doi.org/10.5772/intechopen.95967>
16. Rambe IR, Asri A, Adrial A. Profil Tumor Ganas Ovarium di Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Andalas Periode Januari 2011 Sampai Desember 2012. *Jurnal Kesehatan Andalas*. 2014 Jan 1;3(1).
17. Karlan BY, Bristow RE, Li AJ. *Gynecologic Oncology: Clinical Practice and Surgical Atlas*. McGraw-Hill Medical. 2015.
18. Xie Q, Cheng Z, Chen X, Lobe CG, Liu J. The role of Notch signalling in ovarian angiogenesis. *J Ovarian Res* [Internet]. 2017;10(1):13. Available from: <https://doi.org/10.1186/s13048-017-0308-5>
19. Stanc GM, Souka E, Valavanis C. Recent Advances in Classification and Histopathological Diagnosis of Ovarian Epithelial Malignant Tumours. In: Friedrich M, editor. *Recent Advances, New Perspectives and Applications in the Treatment of Ovarian Cancer* [Internet]. Rijeka: IntechOpen; 2022. p. Ch. 2. Available from: <https://doi.org/10.5772/intechopen.106545>
20. Fujin C, Zhongli C, Minshan C, Yingbo C, Zhongping C, Nianji C, editors. *Buku Ajar Onkologi Klinis*. 2nd ed. Jakarta: Badan Penerbit FK UI; 2013.
21. Yu H, Wang J, Wu B, li J, Chen R. Prognostic significance and risk factors for pelvic and para-aortic lymph node metastasis in type I and type II ovarian cancer: a large population-based database analysis. *J Ovarian Res*. 2023 Dec 1;16(1).

22. Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. *J Mol Cell Biol.* 2020 Sep 1;12(9):674–87.
23. Budiana I. Tumor ovarium prediksi keganasan pra-bedah. *Medicina.* 2013;44:179–85.
24. Aziz Farid, Andrijono, Saifudin. *Onkologi Ginekologi.* 1st ed. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo; 2006.
25. Zhu H, Zhu X, Zheng L, Hu X, Sun L, Zhu X. The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications. *Oncotarget.* 2017 Apr 25;8(17):29395–405.
26. Smith ER, Xu XX. Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion. *Lancet Oncol.* 2008 Nov;9(11):1108–11.
27. Chan KKL, Siu MKY, Jiang Y xin, Wang J jing, Wang Y, Leung THY, *et al.* Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis. *BMC Cancer.* 2017 Dec 31;17(1):606.
28. Zheng G, Yu H, Kanerva A, Forsti A, Sundquist K, Hemminki K. Familial risks of ovarian cancer by age at diagnosis, proband type and histology. *PLoS One.* 2018 Oct 1;13(10).
29. Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE. Long-term mortality among women with epithelial ovarian cancer: A population-based study in British Columbia, Canada. *BMC Cancer.* 2018 Oct 25;18(1).
30. Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M. Epithelial ovarian tumors in the reproductive age group: Age is not an independent prognostic factor. *Cancer.* 1996 Mar 15;77(6):1131–6.
31. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, *et al.* Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. *Br J Cancer.* 2011 Oct 25;105(9):1436–42.
32. Poole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y, *et al.* Hormonal and Reproductive Risk Factors for Epithelial Ovarian Cancer by Tumor Aggressiveness. *Cancer Epidemiology, Biomarkers & Prevention.* 2013 Mar 10;22(3):429–37.
33. Ding N, Zhan J, Shi Y, Qiao T, Li P, Zhang T. Obesity in children and adolescents and the risk of ovarian cancer: A systematic review and dose-response meta-analysis. *PLoS One.* 2022 Dec 1;17(12 December).

34. Azribi F, Abdou E, Dawoud E, Ashour M, Kamal A, Al Sayed M, *et al.* Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study. *BMC Cancer* [Internet]. 2021;21(1):1350. Available from: <https://doi.org/10.1186/s12885-021-09094-8>
35. Farokhi Boroujeni S, Rodriguez G, Galpin K, Yakubovich E, Murshed H, Ibrahim D, *et al.* BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy. *J Ovarian Res* [Internet]. 2023;16(1):231. Available from: <https://doi.org/10.1186/s13048-023-01313-z>
36. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. Ca125 and ovarian cancer: a comprehensive review. Vol. 12, *Cancers*. MDPI AG; 2020. p. 1–29.
37. Matsas A, Stefanoudakis D, Troupis T, Kontzoglou K, Eleftheriades M, Christopoulos P, *et al.* Tumor markers and their diagnostic significance in ovarian cancer. Vol. 13, *Life*. Multidisciplinary Digital Publishing Institute (MDPI); 2023.
38. González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, *et al.* Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Annals of Oncology*. 2023 Oct;34(10):833–48.
39. Berek JS, Hacker NF. *Berek & Hacker's gynecologic oncology*. 7th ed. Lippincott Williams & Wilkins (LWW); 2020. 849 p.
40. Joyner AB, Runowicz CD. Ovarian cancer screening and early detection. Vol. 5, *Women's Health*. 2009. p. 693–9.
41. Funston G, Van Melle M, Baun MLL, Jensen H, Helsper C, Emery J, *et al.* Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: A systematic review of international guidelines. Vol. 19, *BMC Cancer*. BioMed Central Ltd.; 2019.
42. Li J, Sun Y, Zhi X, Sun Y, Abudousalamu Z, Lin Q, *et al.* Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1. *J Ovarian Res*. 2024 Dec 1;17(1).
43. Kong Q, Wei H, Zhang J, Li Y, Wang Y. Comparison of the survival outcomes of laparoscopy versus laparotomy in treatment of early-stage ovarian cancer: a systematic review and meta-analysis. Vol. 14, *Journal of Ovarian Research*. BioMed Central Ltd; 2021.
44. Kurniawan Gondo H. *Terapi Terkini Untuk Kanker Ovarium*. Wijaya Kusuma. 2009;1.

45. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, *et al.* NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. *Journal of the National Comprehensive Cancer Network*. 2019 Aug;17(8):896–909.
46. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *International Journal of Gynecology and Obstetrics*. 2014;124(1):1–5.
47. Wafa M, Braicu Ei, Muallem Mz, Richter R, Taube E, Sehoul J, *et al.* Incidence and Pattern of Spread of Lymph Node Metastasis in Patients With Low-grade Serous Ovarian Cancer. *Anticancer Res [Internet]*. 2019 Oct 1;39(10):5617. Available from: <http://ar.iijournals.org/content/39/10/5617.abstract>
48. Ritch SJ, Telleria CM. The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination. *Front Endocrinol (Lausanne) [Internet]*. 2022;13. Available from: <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.886533>
49. Yu H, Wang J, Wu B, li J, Chen R. Prognostic significance and risk factors for pelvic and para-aortic lymph node metastasis in type I and type II ovarian cancer: a large population-based database analysis. *J Ovarian Res [Internet]*. 2023;16(1):28. Available from: <https://doi.org/10.1186/s13048-023-01102-8>
50. Sood AK. Abstract IA23: hematogenous metastasis of ovarian cancer: rethinking mode of spread. *Cancer Res [Internet]*. 2016 May 26;76(7\_Supplement):IA23–IA23. Available from: <https://doi.org/10.1158/1538-7445.TUMMET15-IA23>
51. Dwi ariningtyas N. CA 125 dan Pemakaian Klinis Dalam Penatalaksanaan Kanker Ovarium. *Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya [Internet]*. 2018 Jul 27;2(2). Available from: <https://journal.um-surabaya.ac.id/qanunmedika/article/view/1657>
52. Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular Biomarkers for the Early Detection of Ovarian Cancer. *Int J Mol Sci [Internet]*. 2022;23(19). Available from: <https://www.mdpi.com/1422-0067/23/19/12041>
53. Giamougiannis P, Martin-Hirsch PL, Martin FL. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia. *Carcinogenesis [Internet]*. 2021 Mar 1;42(3):327–43. Available from: <https://doi.org/10.1093/carcin/bgab010>

54. Howe T, Sokolovsky N, Sayasneh A, Omar K, Tahmasebi F. Raised CA125 – what we actually know *The Obstetrician & Gynaecologist* [Internet]. 2021 Jan 1;23(1):21–7. Available from: <https://doi.org/10.1111/tog.12704>
55. Funston G, Hamilton W, Abel G, Crosbie EJ, Rous B, Walter FM. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. *PLoS Med* [Internet]. 2020 Oct 28;17(10):e1003295-. Available from: <https://doi.org/10.1371/journal.pmed.1003295>
56. Núñez J, Bayés-Genís A, Revuelta-López E, ter Maaten JM, Miñana G, Barallat J, *et al.* Clinical Role of CA125 in Worsening Heart Failure: A BIOSAT-CHF Study Subanalysis. *JACC Heart Fail.* 2020 May 1;8(5):386–97.
57. Bast Jr RC, Lu Z, Han CY, Lu KH, Anderson KS, Drescher CW, *et al.* Biomarkers and Strategies for Early Detection of Ovarian Cancer. *Cancer Epidemiology, Biomarkers & Prevention* [Internet]. 2020 Dec 1;29(12):2504–12. Available from: <https://doi.org/10.1158/1055-9965.EPI-20-1057>
58. Parashar D, Nair B, Geethadevi A, George J, Nair A, Tsaih SW, *et al.* Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. *Cancer Res* [Internet]. 2020 Dec 15;80(24):5554–68. Available from: <https://doi.org/10.1158/0008-5472.CAN-19-3717>
59. Thomakos N, Diakosavvas M, Machairiotis N, Fasoulakis Z, Zarogoulidis P, Rodolakis A. Rare Distant Metastatic Disease of Ovarian and Peritoneal Carcinomatosis: A Review of the Literature. *Cancers (Basel).* 2019 Jul 24;11(8):1044.
60. Liu T, Gao Y, Li S, Xu S. Exploration and prognostic analysis of two types of high-risk ovarian cancers: clear cell vs. serous carcinoma: a population-based study. *J Ovarian Res* [Internet]. 2024;17(1):119. Available from: <https://doi.org/10.1186/s13048-024-01435-y>
61. Gubbels JAA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, *et al.* MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. *Mol Cancer* [Internet]. 2010;9(1):11. Available from: <https://doi.org/10.1186/1476-4598-9-11>
62. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. *Cancers (Basel).* 2020 Dec 11;12(12):3730.

63. Zamani N, Mousavi AS, Akhavan S, Sheikhhasani S, Nikfar S, Feizabad E, *et al.* Uterine involvement in epithelial ovarian cancer and its risk factors. *J Ovarian Res.* 2021 Dec 7;14(1):171.
64. Mei S, Chen X, Wang K, Chen Y. Tumor microenvironment in ovarian cancer peritoneal metastasis. Vol. 23, *Cancer Cell International.* BioMed Central Ltd; 2023.
65. Zheng L, Cui C, Shi O, Lu X, Li Y kun, Wang W, *et al.* Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990–2017. *Gynecol Oncol.* 2020 Oct;159(1):239–47.
66. Dhitayoni IA, Budiana ING. Profil Pasien Kanker Ovarium Di Rumah Sakit Umum Pusat Sanglah Denpasar–Bali Periode Juli 2013–Juni 2014. *E-Jurnal Medika.* 2014;6(3):1–9.
67. Upadhyay A, Garg V, Mathur S, Malik PS, Bhatla N, Kumar S, *et al.* Early-Stage epithelial ovarian cancer: Predictors of survival. *Gynecol Oncol Rep.* 2022;44:101083.
68. Dion L, Mimoun C, Timoh KN, Bendifallah S, Bricou A, Collinet P, *et al.* Ovarian cancer in the elderly: Time to move towards a more logical approach to improve prognosis—a study from the francogyn group. *J Clin Med.* 2020 May 1;9(5).
69. St.Fatimah StF, Latief S, Syahrudin FI, Nulanda M, Mokhtar S. Faktor Risiko Penderita Kanker Ovarium di Rumah Sakit Ibnu Sina Makassar. *Wal’afiat Hospital Journal.* 2023 Jun 27;4(1):46–56.
70. Agusweni T, Dewi YI, Erwin E. Gambaran faktor risiko insiden kanker ovarium di RSUD Arifin Achmad Provinsi Riau. *J Ners Indones.* 2020;11(1):36.
71. Toufakis V, Katuwal S, Pukkala E, Tapanainen JS. Impact of parity on the incidence of ovarian cancer subtypes: a population-based case–control study. *Acta Oncol (Madr).* 2021;60(7):850–5.
72. Kamajaya IGNAT, Brahmantara BN, Wirawan AANAP. Profile of ovarian cancer patients in Mangusada Badung regional public hospital. *Indonesian Journal of Cancer.* 2021;15(3):117–24.
73. Tandarto M, Ginting E, Khairul Nuryanto M, Kedokteran F, Mulawarman U, Samarinda K, *et al.* Hubungan Usia Menarche Dengan Kejadian Kanker Ovarium. *Husada Mahakam : Jurnal Kesehatan.* 2020.
74. Kamajaya IGNAT, Brahmantara BN, Wirawan ANAP. Profile of Ovarian Cancer Patients In Mangusada Badung Regional Public Hospital. *Indonesian Journal of Cancer.* 2021 Oct 22;15(3):117.

75. Kurman RJ, Shih IM. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. *Am J Surg Pathol* [Internet]. 2010;34(3). Available from: [https://journals.lww.com/ajsp/fulltext/2010/03000/the\\_origin\\_and\\_pathogenesis\\_of\\_epithelial\\_ovarian.18.aspx](https://journals.lww.com/ajsp/fulltext/2010/03000/the_origin_and_pathogenesis_of_epithelial_ovarian.18.aspx)
76. Mulawardhana P, Askandar B. Perbandingan antara HE4,CA-125, dan Kombinasi HE4 & CA-125 sebagai Tumor Marker pada Pasien Kanker Ovarium Tipe Epitel. Vol. 19, *Majalah Obstetri & Ginekologi*. 2011.
77. Wijaya R, Murti K, Hafy Z. Hubungan Kadar CA-125 Dengan Subtipe Epitel Tumor Ganas Ovarium Pada Penderita Yang Dirawat Di RSUP Dr. Mohammad Hoesin Palembang Tahun 2013-2016. *Majalah Kedokteran Sriwijaya*. 2017;49(4):197–204.
78. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. *Cancers (Basel)*. 2020 Dec 11;12(12):3730.
79. Yuan Q, Song J, Yang W, Wang H, Huo Q, Yang J, *et al.* The effect of CA125 on metastasis of ovarian cancer: old marker new function. *Oncotarget*. 2017 Jul 25;8(30):50015–22.
80. Zhang H, Huo Q, Huang L, Cheng Y, Liu Y, Bao H. Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer Patients with Low CA125 Concentration. *Biomed Res Int*. 2019 Jun 25;2019:1–7.
81. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - A review of the epidemiological literature. Vol. 2, *Journal of Ovarian Research*. 2009.
82. Saygili U, Guclu S, Uslu T, Erten O, Dogan E. The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. *International Journal of Gynecological Cancer*. 2002 Sep;12(5):438–42.